Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features.

BACKGROUND There is currently no standard treatment for patients with castration-resistant prostate cancer (CRPC) whose disease progresses after docetaxel-based chemotherapy. The purpose of this study was to prospectively assess the anticancer activity and tolerance of the carboplatin-etoposide combination in this setting while evaluating neuroendocrine (NE) features. PATIENTS AND METHODS Patients with CRPC and metastases who experienced failure after first-line docetaxel-based chemotherapy were treated with carboplatin (area under the curve 5, day 1) and etoposide (80 mg/m(2)/day from days 1 to 3), repeated every 3 weeks. The association between serum chromogranin A (CgA), neuron-specific enolase (NSE), prostate-specific antigen-doubling time (PSADT), and treatment efficacy was studied. RESULTS Forty patients with CRPC who had received docetaxel with (n = 20) or without (n = 20) estramustine received the carboplatin-etoposide combination as second-line chemotherapy. A prostate-specific antigen (PSA) response defined as a PSA decline > or =50% was achieved in nine patients (23%). Median progression-free survival (PFS) was 2.1 months (range 0.6-9.6) and median overall survival was 19 months (range 2.1-27.7). Pain response was achieved in 15 (53%) of 28 assessable patients. Toxicity, including mainly grades 3-4 anaemia (25%) and febrile neutropenia in only 2% of patients, was manageable. Baseline CgA, NSE, or PSADT were not significant predictors for response or PFS. The PSA response rates were 18% and 31% in patients with normal and elevated serum CgA, respectively. It was 25% and 20%, respectively, in patients with normal and elevated serum NSE. CONCLUSIONS Combining carboplatin and etoposide as second-line chemotherapy in patients with CRPC is active and well tolerated in spite of a limited PFS. Activity was observed in CRPC with and without NE features.

[1]  I. Tannock,et al.  Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  R de Crevoisier,et al.  The postchemotherapy PSA surge syndrome. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[3]  W. Oh,et al.  A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone‐refractory prostate cancer who are refractory to docetaxel , 2008, Cancer.

[4]  J. Pignon,et al.  Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. , 2007, The Lancet. Oncology.

[5]  M. Gross,et al.  Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients , 2007, Cancer.

[6]  C. Sternberg,et al.  Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: Results of a randomized phase III trial , 2007 .

[7]  W. Oh,et al.  Response to Vinorelbine With or Without Estramustine as Second-Line Chemotherapy in Patients with Hormone-Refractory Prostate Cancer , 2007, Cancer journal.

[8]  W. Oh,et al.  Is there a role for platinum chemotherapy in the treatment of patients with hormone‐refractory prostate cancer? , 2007, Cancer.

[9]  P. di Sant'Agnese,et al.  Immunohistochemical characterization of neuroendocrine cells in prostate cancer , 2006, The Prostate.

[10]  J. Manola,et al.  Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. , 2006, Urology.

[11]  J. Bay,et al.  Circulating chromogranin a and hormone refractory prostate cancer chemotherapy. , 2006, The Journal of urology.

[12]  C. Kollmannsberger,et al.  First‐ and second‐line chemotherapy with docetaxel or mitoxantrone in patients with hormone‐refractory prostate cancer , 2006, Cancer.

[13]  A. Lazaris,et al.  Evaluation of neuroendocrine staining and androgen receptor expression in incidental prostatic adenocarcinoma: prognostic implications. , 2005, Urology.

[14]  P. di Sant'Agnese,et al.  Tumorigenesis and Neoplastic Progression Differential Expression of Interleukin-8 and Its Receptors in the Neuroendocrine and Non-Neuroendocrine Compartments of Prostate Cancer , 2005 .

[15]  L. Dogliotti,et al.  Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease. , 2005, Endocrine-related cancer.

[16]  P. Abrahamsson,et al.  Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. , 2005, European urology.

[17]  C. Tangen,et al.  Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. , 2004, The New England journal of medicine.

[18]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[19]  R. Matusik,et al.  NE-10 Neuroendocrine Cancer Promotes the LNCaP Xenograft Growth in Castrated Mice , 2004, Cancer Research.

[20]  C. Gregory,et al.  Neuroendocrine cell differentiation in the CWR22 human prostate cancer xenograft: Association with tumor cell proliferation prior to recurrence , 2004, The Prostate.

[21]  David C. Smith,et al.  Phase II trial of paclitaxel, estramustine, etoposide, and carboplatin in the treatment of patients with hormone‐refractory prostate carcinoma , 2003, Cancer.

[22]  J. Lafitte,et al.  A phase II randomised trial comparing the cisplatin-etoposide combination chemotherapy with or without carboplatin as second-line therapy for small-cell lung cancer. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  P. Thall,et al.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  P. Babb,et al.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons , 2002, BJU international.

[25]  P. Babb,et al.  Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part II: individual countries , 2002, BJU international.

[26]  V. Reuter,et al.  Cytotoxic Treatment of Aggressive Prostate Tumors with or without Neuroendocrine Elements , 2002, Acta oncologica.

[27]  J. Shuster,et al.  Results of a Randomized Phase III Trial in Children and Adolescents with Advanced Stage Diffuse Large Cell Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Study , 2002, Leukemia & lymphoma.

[28]  L. Dogliotti,et al.  Circulating neuroendocrine markers in patients with prostate carcinoma , 2000, Cancer.

[29]  B. Freidlin,et al.  Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  A. Bjartell,et al.  Neuroendocrine differentiation in prostatic carcinoma during hormonal treatment. , 1998, Urology.

[31]  T. H. van der Kwast,et al.  The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. , 1997, The Journal of urology.

[32]  M. Stridsberg,et al.  Neuroendocrine differentiation in carcinomas of the prostate: Do neuroendocrine serum markers reflect immunohistochemical findings? , 1997, The Prostate.

[33]  J P Pignon,et al.  Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. , 1993, The New England journal of medicine.